Financials Xiamen Amoytop Biotech Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
60.51 ^CNY	-0.31%		-6.43%	+15.59%

Apr. 22	Xiamen Amoytop Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 18	China Stocks Advance Over Positive Economic Data; Amoytop Biotech Rises 6%	MT

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	13,872	11,911	15,837	21,296	24,615	-	-
Enterprise Value (EV) ¹	13,872	11,911	15,837	21,296	24,615	24,615	24,615
P/E ratio	118 x	65.1 x	54.8 x	38.2 x	32.5 x	24 x	17.6 x
Yield	0.15%	-	-	0.78%	0.21%	0.61%	0.44%
Capitalization / Revenue	17.5 x	-	-	10.1 x	8.7 x	6.6 x	5.01 x
EV / Revenue	17.5 x	-	-	10.1 x	8.7 x	6.6 x	5.01 x
EV / EBITDA	-	-	-	-	26.4 x	19.8 x	14.7 x
EV / FCF	-	-	-	-	46.9 x	29.5 x	21.9 x
FCF Yield	-	-	-	-	2.13%	3.39%	4.56%
Price to Book	13.9 x	-	-	11.4 x	9.6 x	7.18 x	5.15 x
Nbr of stocks (in thousands)	406,800	406,800	406,800	406,800	406,800	-	-
Reference price ²	34.10	29.28	38.93	52.35	60.51	60.51	60.51
Announcement Date	2/26/21	2/25/22	3/30/23	2/24/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	-	793.9	-	-	2,100	2,830	3,729	4,917
EBITDA ¹	-	-	-	-	-	933.5	1,243	1,680
EBIT ¹	-	158.1	-	-	680.7	923.6	1,258	1,679
Operating Margin	-	19.92%	-	-	32.41%	32.63%	33.75%	34.15%
Earnings before Tax (EBT) ¹	-	139.1	-	-	640.7	883.2	1,215	1,638
Net income ¹	64.29	116.6	181.3	287	555.4	756.1	1,028	1,403
Net margin	-	14.68%	-	-	26.45%	26.71%	27.56%	28.53%
EPS ²	0.1800	0.2900	0.4500	0.7100	1.370	1.860	2.524	3.445
Free Cash Flow ¹	-	-	-	-	-	525.3	835.6	1,122
FCF margin	-	-	-	-	-	18.56%	22.41%	22.81%
FCF Conversion (EBITDA)	-	-	-	-	-	56.27%	67.22%	66.76%
FCF Conversion (Net income)	-	-	-	-	-	69.48%	81.32%	79.96%
Dividend per Share ²	-	0.0500	-	-	0.4100	0.1250	0.3700	0.2650
Announcement Date	3/29/20	2/26/21	2/25/22	3/30/23	2/24/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	-	-	-	-	-	525	836	1,122
ROE (net income / shareholders' equity)	-	12.7%	-	-	34%	29.9%	31.5%	29.8%
ROA (Net income/ Total Assets)	-	-	-	-	-	27%	27.3%	27.7%
Assets ¹	-	-	-	-	-	2,800	3,771	5,064
Book Value Per Share ²	-	2.460	-	-	4.610	6.310	8.430	11.70
Cash Flow per Share ²	-	0.2300	-	-	1.260	1.910	2.420	3.280
Capex ¹	-	119	-	-	288	168	172	168
Capex / Sales	-	14.96%	-	-	13.73%	5.95%	4.6%	3.41%
Announcement Date	3/29/20	2/26/21	2/25/22	3/30/23	2/24/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

60.51 CNY

Average target price

86.1 CNY

Spread / Average Target

+42.29%

	1st Jan change	Capi.
XIAMEN AMOYTOP BIOTECH CO., LTD.	+15.59%	3.41B
CSL LIMITED	-3.45%	87.17B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.1B
BIOGEN INC.	-16.98%	31.38B
UCB	+57.86%	25.12B
BIOMARIN PHARMACEUTICAL INC.	-16.24%	15.59B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	12B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.8B
INCYTE CORPORATION	-17.10%	11.8B
SWEDISH ORPHAN BIOVITRUM AB	+6.89%	8.81B